Related Experiment Video
Updated: Jul 10, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues
1Mount Sinai School of Medicine, New York, NY 10029, USA. Louis.Aledort@mountsinai.org
Summary
Factor VIII inhibitor bypassing activity (FEIBA) effectively manages bleeding in hemophilia patients with inhibitors. Despite safety concerns, FEIBA demonstrates a low thrombosis risk and excellent safety and tolerability.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Hemophilia A and B patients with high-titre inhibitors often require bypassing therapy.
- Factor VIII inhibitor bypassing activity (FEIBA) is a common treatment option.
- Concerns regarding FEIBA's safety have limited its use in some clinical settings.
Purpose of the Study:
- To evaluate the safety and efficacy of FEIBA in patients with hemophilia and inhibitors.
- To address concerns about thrombosis, anamnesis, and pathogen safety associated with FEIBA.
Main Methods:
- Review of existing literature.
- Analysis of clinical trial data for FEIBA.
Main Results:
- FEIBA exhibits a low prevalence of thrombosis.
- Anamnesis events associated with FEIBA do not significantly impact hemostatic efficacy.
- FEIBA demonstrates excellent pathogen safety and clinical tolerability.
Conclusions:
- FEIBA is a safe and effective bypassing agent for managing bleeding in hemophilia patients with inhibitors.
- The data support the continued use of FEIBA in acute, surgical, and prophylactic settings.
- FEIBA's favorable safety profile outweighs reported concerns, supporting its clinical utility.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...